YF-VAX 109648 PFU / 0.5 ML
YELLOW FEVER VACCINE : 109648 PFU / 0.5 ML · DIN 00428833 · SANOFI PASTEUR LIMITED
Health Canada status: MARKETED
What is YF-VAX?
YF-VAX 109648 PFU / 0.5 ML contains YELLOW FEVER VACCINE : 109648 PFU / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 00428833, held by SANOFI PASTEUR LIMITED, supplied as POWDER FOR SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 26-May-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is YF-VAX used for?
Active immunization for the prevention of yellow fever in persons 9 months of age or older. Recommended for travel to endemic zones or where required by international law.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00428833 |
|---|---|
| Brand name | YF-VAX |
| Generic / active ingredient | YELLOW FEVER VACCINE : 109648 PFU / 0.5 ML |
| Manufacturer | SANOFI PASTEUR LIMITED |
| Strength | 109648 PFU / 0.5 ML |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | J07BL01 YELLOW FEVER, LIVE ATTENUATED |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-May-2006 |
| Original market date | 1978-12-31 00:00:00 |
How is it administered?
Single subcutaneous injection of 0.5 mL. Reconstitute with provided 0.9% Sodium Chloride diluent and use within 60 minutes. Booster recommended every 10 years by International Health Regulations.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 2° to 8°C (35° to 46°F). Do not freeze. Reconstituted vaccine must be used within 60 minutes.
How is it supplied?
Single dose vial with 0.6 mL vial of 0.9% Sodium Chloride Injection USP diluent.
Contraindications
Hypersensitivity to egg/chicken protein; altered immune status (immunosuppression, HIV, thymic disease); infants <9 months of age.
Warnings and precautions
Risk of Yellow Fever Vaccine-Associated Viscerotropic Disease (YFV-AVD) and Neurotropic Disease (YFV-AND), especially in those >60 years or immunocompromised. Monitor for anaphylaxis.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.